GlassScriptPhysician profile
Candace Percifull
NPI 1689941817
$2,498.05
in general payments reported to CMS, 2019-2025
15 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $132 · 2022: $203 · 2023: $421 · 2024: $636 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,162.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $582.19 | 2022-2025 | |
| Pfizer INC. | $444.56 | 2023-2025 | |
| Novo Nordisk INC | $305.99 | 2021-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $302.35 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Neurocrine Biosciences, INC. | $213.76 | 2022-2024 | Ingrezza |
| Exact Sciences Corporation | $152.56 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $129.22 | 2023 | Quviviq |
| Lilly USA, LLC | $117.23 | 2022-2025 | Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $100.84 | 2025 | Voquezna |
| Amgen INC. | $42.82 | 2025 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.95 | 2022 | |
| Organon LLC | $26.02 | 2025 | Nexplanon |
| Teva Pharmaceuticals USA, INC. | $20.38 | 2024 | Ajovy |
| Alkermes, INC. | $16.73 | 2021 | |
| Nevro Corp. | $15.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candace Percifull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.